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Abstract Thyroid transcription factor I (TTF-1) plays a critical 
role in thyroid organogenesis and in the control of expression of 
several thyroid-specific genes, like those coding for thyroglobulin 
and thyroperoxidase. We have expressed the isolated DNA- 
binding homeodomain of TTF-1 in cultured thyroid cells by 
transient transfection. A specific reduction in the activity of co- 
transfected thyroglobulin and tbyroperoxidase promoters was 
observed in the presence of the isolated TTF-1 homeodomain, as 
compared to their activity measured in the presence of a mutated 
homeodomain unable to bind DNA. The activity of the SV40 
early promoter, used as a control, was only marginally affected 
in these experiments. The transactivation-deficient form of TTF- 
1 described here may thus be used for investigating other cellular 
processes that are dependent on TTF-1 transcriptional activity. 
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1. Introduction 
Thyroid transcription factor I (TTF-1) is a homeodomain- 
containing protein that was identified first in the thyroid and 
was shown to present a restricted tissue distribution [1,2]. It 
controls the expression of several thyroid-specific (thyroglobu- 
lin, thyroperoxidase, TSH receptor) [3] and pulmonary-specif- 
ic (surfactant proteins A, B and C) genes [4-61. Targeting of 
the TTF-1 gene in mice resulted in a lethal phenotype with 
defects in the organogenesis of the thyroid, lung, ventral fore- 
brain and pituitary [7]. In vitro studies using TTF-1 antisense 
oligonucleotides also indicated that this factor plays a role in 
the control of thyroid cell proliferation [8] and lung branching 
morphogenesis [9]. 
The investigation of structure/function relationships in the 
TTF-1 molecule revealed that the central homeodomain is 
flanked on both sides by transcriptional activation regions 
[lo]. The isolated homeodomain itself, produced in bacteria, 
exhibited all the DNA-binding properties of the entire protein 
as assayed in vitro [l 11. On the basis of these data, it was 
tempting to speculate that the isolated TTF-1 homeodomain 
would behave as a dominant negative form of TTF-1 when 
overexpressed in the cell. We have generated an expression 
construct that directs the production of the isolated TTF-1 
homeodomain in eukaryotic cells and we show here that the 
expressed protein is able to repress TTF-1 transcriptional ac- 
tivity in transfected cells. 
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2. Materials and methods 
2.1. DNA constructions 
Cloning experiments were performed according to standard proce- 
dures [12]. Plasmid bTgCAT6 was constructed by transferring the 
HindIII-Sac1 subfragment from plasmid TgCATl4M [13] that con- 
tains the bovine thyroglobulin promoter region (from -172 to +9) 
fused to the CAT coding sequence into the pBLCAT6 vector [14]. 
Plasmid bENHbTgCAT6 was obtained by inserting the upstream en- 
hancer element from the bovine thyroglobulin gene (- 1906 to - 1744) 
[15] into HindIII+BamHI cleaved bTgCAT6. To construct the expres- 
sion plasmid HD, the sequences encoding the homeodomain of dog 
TTF-1 [16] were amplified using the following primers: 5’ primer (64- 
mer): GGCGAATTCCGCCATGGCACCAAAAAAGAAGAGAA- 
AGGTGGAGGCCCCGCTGCCAAGCGCACCG; 3’ primer (29- 
mer): GGCGGATCCTACTGCGCCGCCITGTCCTT. The 5’ pri- 
mer contains a translation initiation ATG codon followed by the 
sequences coding for the nuclear localization signal from SV40 large 
T antigen [17]. The amplified fragment was cloned into EcoRI+Bam- 
HI cleaved pSG5 expression vector (Stratagene, La Jolla, CA, USA) 
and sequenced in order to exclude the presence of PCR-introduced 
mutations. The construction of the HDm plasmid involved the muta- 
genesis of the sequences coding for residues 48-50 in the TTF-1 home- 
odomain in a first PCR reaction using the following 5’ primer (33- 
mer; introduces a Not1 restriction site in the sequence): CAGGT- 
CAAAATCGCGGCCGCGAACCACCGCTAC, and the same 3’ pri- 
mer as used above. The 80 bp PCR product was purified, treated with 
T4 DNA polymerase in the presence of the four dNTPs and used as a 
3’ mega-primer [18] in a second PCR reaction (5’ primer: 64 base 
primer used for HD construction). The amplified fragments were 
cloned in pSG5 and clones containing the desired mutation were 
selected on the basis of the presence of the expected Not1 restriction 
site. 
2.2. Cell culture, DNA transfections and CAT assays 
FRTLS cells were maintained in Fl2-Coon’s medium supplemented 
with 5% fetal calf serum, 5 &ml transferrin, 1 pg/ml insulin, 1 mu/ml 
TSH, 100 W/ml penicillin, 100 &ml streptomycin and 2.5 pg/ml 
fungizone. Co-transfections were achieved using the calcium-phos- 
phate technique [19] and a 1:l ratio of expression and reporter con- 
structs. Total amounts of DNA engaged in the transfection varied 
from 4 to 8 pg per 60 mm diameter culture dish. CAT assays were 
performed as described [15]. The background value represented less 
than 10% of the lowest value measured in the assay. 
3. Results and discussion 
We decided to investigate the effect of the production in the 
cell of the isolated TTF-1 homeodomain on the activity of 
transfected promoters known to be transactivated by the en- 
dogenous TTF-1. In order to ensure proper nuclear targeting 
of the produced protein, the sequences coding for the TTF-1 
homeodomain were fused in 3’ of the sequences encoding the 
nuclear localization signal of the SV40 large T antigen using 
the PCR technique. The resulting DNA fragment was cloned 
into the pSG5 vector (Stratagene), giving the expression con- 
struct ‘HD’. As we needed an appropriate control in the co- 
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that the expressed TTF-1 homeodomain, when able to bind 
DNA, could compete out transactivation by the endogenous 
factor. However, we noted that no complete suppression of 
the activity of the reporter promoters was obtained and, con- 
comitantly, that a slight nonspecific decrease in the activity of 
the SV40 promoter was observed in most experiments. The 
extent of this nonspecific effect was related to the extent of 
repression on the activity of the thyroid-specific promoters in 
all experiments. Extreme experimental results (expressed in 
the form of HD/HDm values as in Fig. 1) were as follows: 
experiment 1: bTg: 0.4 + 0.05 and SV40: 1 f 0.15 (no nonspe- 
cific effect); experiment 2: bTg: 0.22+0.04 and SV40: 
0.36 f 0.03 (large nonspecific effect but still significant specific 
effect). No correlation was found between the amount of 
DNA (total of 4-8 ug per dish; a 1: 1 ratio of expression to 
reporter construct was maintained) engaged in the transfec- 
tion and the extent of repression (both specific and nonspe- 
cific). As the results of duplicates within a given experiment 
were consistent, it most likely resulted from differences in 
transfection efficiencies between the individual transfection 
experiments. It is conceivable that a higher transfection effi- 
ciency will result in an overall increase in the production of 
the transactivation-deficient form, which would in turn entail 
a more pronounced repression. At high titers, DNA binding 
by the TTF-1 homeodomain would then also affect transcrip- 
tional activity in a nonspecific way. This view is supported by 
the data recently reported by Fabbro et al. [22] indicating that 
the panel of sequences recognized by the TTF-1 homeodo- 
main is wider than expected previously. 
This difficulty requires that appropriate experimental con- 
ditions should be defined, and appropriate controls should be 
used, in each application in order to achieve a compromise 
allowing the clear detection of the specific effects. As shown 
here, provided adequate conditions are found, the expression 
of the transactivation-deficient form of TTF-1 described may 
specifically interfere with TTF-1 action. This ability could be 
used to characterize other cellular processes relying on the 
transactivation potential of TTF- 1. 
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Fig. 1. Results of the co-transfection experiments in FRTL-5 cells 
expressed as the ratio of CAT activity measured in the presence of 
the wild-type homeodomain (HD) to that measured in the presence 
of the mutated homeodomain (HDm) for each reporter construct 
(see also text; the number of independent transfection experiments 
done appears in parentheses). 
transfection experiments, a second expression construct, 
‘HDm’, was also generated. This construct specifies the pro- 
duction of a mutated homeodomain in which residues 48-50 
(Trp-Phe-Gln, in helix III of the homeodomain) are replaced 
by alanines. This mutation is known to result in a null DNA- 
binding phenotype [20]. 
The reporter constructs contained the chloramphenicol 
acetyltransferase (CAT) gene under the control of thyroid- 
specific promoter elements from the thyroglobulin and thyro- 
peroxidase genes. Construct bTgCAT6 (bTg in Fig. 1) harbors 
the proximal promoter region from the bovine thyroglobulin 
gene [13], and construct bENHbTgCAT6 (bENHTg in Fig. 1) 
contains in addition the upstream element from the same gene 
[15]. In construct pTPOCAT (TPO in Fig. l), the CAT gene is 
under the control of the human thyroperoxidase promoter 
[21]. All of these regulatory regions have been shown to be 
functionally dependent on TTF-1 in transfection experiments 
[3]. The pSV2CAT plasmid [19] (SV40 in Fig. 1) was used as a 
control reporter construct, as there are at present no indica- 
tions that the activity of the SV40 early promoter depends on 
the presence of transcriptionally competent TTF-1. 
The co-transfection experiments were conducted in the thy- 
roid cell line FRTL-5. These cells express the endogenous 
TTF-1 gene and contain the other factors required for the 
activation of the thyroid-specific promoters. Each reporter 
construct was co-transfected with the HD and the HDm ex- 
pression plasmids in separate dishes, in duplicate. CAT activ- 
ities were measured and results were expressed as the ratio of 
CAT production obtained in the presence of HD (wild-type 
homeodomain) to that obtained in the presence of HDm (mu- 
tated homeodomain). As is apparent in Fig. 1, when the re- 
porter construct harbored a TTF-l-dependent promoter (bTg, 
bENHTg and TPO), this ratio was significantly lower than 
that measured for pSV2CAT (SV40). This demonstrated 
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